In the phase III CLEOPATRA trial the progression-free survival after first-line dual HER2 blockade with trastuzumab plus pertuzumab was shorter in patients with PIK3CA mutant breast cancer than in patients with wild-type (WT) PIK3CA tumors (6). Here, ERBB2 is linked to breast carcinoma.